leucovorin calcium

P2, N=64, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

Olaparib therapy was initiated and the metastases responded well (partial response). PACC is a BRCA2-associated cancer which may respond well to PARP inhibitors.

The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity.

P1/2, N=62, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P1/2, N=98, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting

P3, N=778, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | N=522 --> 778

P2, N=40, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P3, N=438, Active, not recruiting, University Hospital Schleswig-Holstein | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> May 2024

P1/2, N=120, Recruiting, Karyopharm Therapeutics Inc | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P1, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2025

P3, N=115, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2024 --> Jun 2025

P3, N=1007, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2024 --> Jun 2025

Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphological differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis.

Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment. Additionally, high AST value and pancreatic head cancer may be risk factors for leukopenia during nal-IRI/FL treatment.

P2, N=1044, Completed, Hoffmann-La Roche | N=609 --> 1044

P1/2, N=40, Completed, AbbVie | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2

Research on the relationship between HIF-1α levels and the clinical effect of oxaliplatin is lacking, and whether liensinine regulates HIF-1α is unknown. Our findings suggest that liensinine overcomes the resistance of colorectal cancer cells to oxaliplatin by suppressing HIF-1α levels to inhibit autophagy. Our findings can contribute to improving prognosis following colorectal cancer therapy.

P1/2, N=95, Completed, UCB Biopharma SRL | Active, not recruiting --> Completed

These findings indicate that the basic time parameter of ETS could not realistically be employed in routine oncology care of patients with metastatic colorectal cancer (mCRC) in the Czech Republic, unless there would be a strict request to perform TRFC by week 8 since the initiation of the therapy. In addition, the frequency of objective tumor response to first-line therapy with cetuximab + chemotherapy was evaluated. Based on the relative regression in the sum of diameters of measurable metastatic lesions, unconfirmed partial responses were achieved in 42.4 % and unconfirmed complete response in 8.6% of patients, altogether corresponding to the overall response rate of 51% with first-line therapy. The frequency of responses was higher among patients with left than right sided primary tumors. It seems that the regimen of cetuximab/FOLFOX might be more active in frontline therapy of right sided RAS wild type mCRC than cetuximab/FOLFIRI.

P4, N=36, Recruiting, University of Chicago | Trial completion date: Mar 2026 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2025

In the case of chemotherapy FOLFIRI, the increased expression of ABC transcripts and proteins induced by T3 treatment is responsible for the augmented efflux of 5-FU and Irinotecan from the cancer cells. Taken together, these mechanisms contribute to the decreased efficacy of the chemotherapy and allow cells to escape the treatment. Created with BioRender.com .

P3, N=560, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2028 --> Nov 2034

P1/2, N=40, Recruiting, Seagen Inc. | N=120 --> 40 | Trial primary completion date: May 2024 --> Mar 2025

P1, N=3, Terminated, National Cancer Institute (NCI) | Active, not recruiting --> Terminated; Due to Covid and poor enrollment

P1, N=10, Active, not recruiting, National Cancer Institute (NCI) | N=90 --> 10 | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Mar 2024

The findings suggest the combination of PD-1-inhibitor and mFOLFOX6 showed efficacy and acceptable toxicity for locally advanced GC. Extended follow-up is required to determine the duration of the response. This study lays essential groundwork for developing precise neoadjuvant regimens.

P=N/A, N=36, Recruiting, HK inno.N Corporation

P2, N=70, Recruiting, Inspirna, Inc. | N=50 --> 70

From an initial pool of 1345 articles, 11 relevant studies were selected for inclusion, encompassing a diverse range of systemic treatments, including panitumumab combined with FOLFOX4 and FOLFIRI, irinotecan paired with panitumumab, regorafenib followed by cetuximab ± irinotecan and vice versa, and panitumumab as a maintenance therapy post-induction...Notably, cetuximab + FOLFIRI was associated with a median survival of 25.7 months versus 16.4 months for FOLFIRI alone, emphasizing the potential benefits of integrating targeted therapies with chemotherapy. In conclusion, the review underscores the significant impact of systemic treatments, particularly targeted therapies and their combinations with chemotherapy, on survival outcomes and QoL in patients with RAS-positive stage IV colorectal cancer, and the need for personalized treatment.

Combination treatment with leucovorin and oxaliplatin or irinotecan improves the effectiveness of 5FU therapy. In vitro assays with human colon cancer cell lines showed that therapy with TcES+5FU significantly reduced cell proliferation and migration by modulating the P53 and P21 signaling pathways. Our findings demonstrate, for the first time in vivo, that helminth-derived excreted/secreted products may potentiate the effect of 5FU on established colon tumors.

This study aimed to examine the effectiveness of the best response rate (BRR) as a surrogate for overall survival (OS), using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), in patients with unresectable hepatocellular carcinoma (HCC) undergoing hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) combined with molecular targeting and immunotherapy. Thus, by calculating the BRR, the prognosis of HCC patients after combination therapy can be predicted. Inferior vena cava tumor thrombus and baseline tumor size were closely associated with the BRR.

P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026

We proposed that miR-92a-3p impairs FOLFOX (fluorouracil/oxaliplatin) chemotherapy response by upregulating the expression of chemoresistance biomarker genes through the activation of β-catenin and epithelial-mesenchymal transition (EMT)...Furthermore, even though miR-92a-3p affects ERCC2, XRCC1, E-cadherin, and β-catenin mRNA levels, it has no influence on their protein expression. We found that miR-92a-3p does not upregulate the expression of proteins of DNA-repair pathways and other genes involved in FOLFOX chemotherapy resistance.

P2, N=120, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024

P3, N=680, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024

P1/2, N=66, Not yet recruiting, Amsterdam UMC, location VUmc

P2, N=25, Not yet recruiting, Mayo Clinic

P2, N=60, Active, not recruiting, Salspera LLC | Recruiting --> Active, not recruiting

P=N/A, N=647, Completed, iOMEDICO AG | Active, not recruiting --> Completed

P3, N=668, Ongoing, 1Globe Health Institute

P2, N=150, Recruiting, Leap Therapeutics, Inc. | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025